dipyridamole has been researched along with Infantile Respiratory Distress Syndrome in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, P | 1 |
| Hayden Smith, J | 1 |
| Haynes, S | 1 |
| Hasan, A | 1 |
| Hamilton, JR | 1 |
1 other study available for dipyridamole and Infantile Respiratory Distress Syndrome
| Article | Year |
|---|---|
Use of dipyridamole for pulmonary hypertension following repair of total anomalous pulmonary venous drainage.
Topics: Dipyridamole; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Postoperative Complications; P | 2000 |